ABCB1 and colon carcinoma: The 3.6 inhibited the viability of epidermoid carcinoma (KB3-1 and its ABCB1-overexpressing subline KBC-1) and colon carcinoma (HCT116wt and its p53 knockdown subline HCT116 p53-/-) cells.